BTLA-conjugated (CD272) antibodies for modulating immune responses and treating diseases

Novel anti-BTLA antibodies modulate immune responses by blocking or enhancing BTLA-HVEM interactions, addressing the limitations of existing immunotherapies and providing effective treatments for cancer and autoimmune diseases.

JP7875929B2Active Publication Date: 2026-06-18CURIA IP HOLDINGS LLC +1
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2024206358
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-04-01
Filing Date
2024-11-27
Publication Date
2026-06-18
Estimated Expiration
2040-03-31

Smart Images

  • Figure 0007875929000026
    Figure 0007875929000026
  • Figure 0007875929000027
    Figure 0007875929000027
  • Figure 0007875929000028
    Figure 0007875929000028
Patent Text Reader

Abstract

To provide novel anti-BTLA antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer or autoimmune disease.SOLUTION: Provided are antibodies comprising a heavy chain variable region comprising a specific amino acid sequence and a light chain variable region comprising another specific amino acid sequence, pharmaceutical compositions comprising the antibodies, and therapeutic methods of using the antibodies and pharmaceutical compositions for the treatment of diseases such as cancer or autoimmune disease.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Fully human antibodies against BTLA

    JP2013500715A

  • Modulation of immune responses using btla agonistic antibodies

    JP2018521959A

  • Antibodies specific for glycosylated BTLA (B- and T-lymphocyte attenuating factor)

    JP2019502405A

  • Antibodies having specificity for BTLA and uses thereof

    WO2017144668A1